Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo

Trastuzumab, a humanized monoclonal antibody targeting HER2, has demonstrated clinical benefits for women with HER2-positive breast cancer; however, trastuzumab resistance remains the biggest clinical challenge. In this study, results showed that tunicamycin, an inhibitor of N-glycosylation, synergi...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xiqian, Zhang, Xiaobing, Li, Hui, Huang, Shengshi, Zhang, Shu, Wang, Fengshan, Shi, Yikang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770746/
https://www.ncbi.nlm.nih.gov/pubmed/26498681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770746/
https://www.ncbi.nlm.nih.gov/pubmed/26498681

Ejemplares similares